OTCMKTS:CUBT Curative Biotechnology (CUBT) Stock Price, News & Analysis → Protect Yourself While There’s Still Time … (From Weiss Ratings) (Ad) Free CUBT Stock Alerts $0.03 0.00 (0.00%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$0.03▼$0.0350-Day Range$0.02▼$0.0452-Week Range$0.01▼$0.04Volume5,000 shsAverage Volume238,568 shsMarket Capitalization$19.69 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartFinancialsSEC FilingsShort InterestStock AnalysisChartFinancialsSEC FilingsShort Interest Get Curative Biotechnology alerts: Email Address Ad Weiss RatingsProtect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late. About Curative Biotechnology Stock (OTCMKTS:CUBT)Curative Biotechnology, Inc., a development-stage biomedical company, focuses on novel treatments for rare diseases. The company focuses on therapies with potentially accelerated development paths as a result of the disease, the nature of the therapeutic itself, or the stage of clinical development. Its pipeline candidates include CURB906, an antibody-drug conjugate for targeting CD56 positive brain tumors; and IMT504, a novel immune therapy to treat rabies. The company has an agreement with Mid-Atlantic BioTherapeutics, Inc. to develop the COVID-19 vaccine. Curative Biotechnology, Inc. was founded in 1995 and is based in Boca Raton, Florida.Read More CUBT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CUBT Stock News HeadlinesMarch 31, 2024 | globenewswire.comCurative Biotechnology, Inc. Announces Nomination of Dr. Theresa Heah to Board of DirectorsMarch 29, 2024 | seekingalpha.comSFRX Seafarer Exploration Corp.April 27, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.March 22, 2024 | globenewswire.comCurative Biotechnology, Inc. Announces Nomination of Dr. Theresa Heah to Board of DirectorsJanuary 22, 2024 | insidermonkey.comShould You Expect Strong Financial Growth For Legend Biotech Corporation (LEGN)?October 31, 2023 | finanznachrichten.deCurative Biotechnology, Inc.?: Curative Biotechnology, Inc. Announces Nomination of Dr. Jeffrey Liebmann to Board of DirectorsAugust 18, 2023 | thestreet.com3 Best Biotech Stocks to Add to Your PortfolioJune 6, 2023 | finance.yahoo.comCurative Biotechnology Announces Establishment of Japanese Subsidiary for Licensing Transactions and Asset AcquisitionsApril 27, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.June 2, 2023 | bizjournals.comSacramento Biotech NewsMay 24, 2023 | finance.yahoo.comCurative Biotechnology, Inc. Files Patent on Ophthalmic FormulationJanuary 5, 2023 | finanznachrichten.deCurative Biotechnology, Inc.?: Curative Biotechnology Announces Completion of IND Enabling Reformulated Metformin HCL Eye Drop StudyNovember 12, 2022 | finance.yahoo.comCurative Biotechnology, Inc. (CUBT)November 8, 2022 | seekingalpha.comCurative Biotechnology refiles for NYSE uplisting, $8M offeringOctober 20, 2022 | finanznachrichten.deCurative Biotechnology, Inc.: Curative Biotechnology Announces Intent to Uplist to NYSE American ExchangeSeptember 30, 2022 | seekingalpha.comCurative Biotechnology files for NYSE American uplisting, $8M IPOSeptember 26, 2022 | benzinga.comCurative Biotechnology Stock (OTC:CUBT), Short Interest ReportSeptember 22, 2022 | seekingalpha.comCUBT Curative Biotechnology, Inc.June 16, 2022 | finance.yahoo.comCurative Biotechnology Inc. Adds Biotech Veteran Lawrence S. Zaslow to Board of DirectorsMay 12, 2022 | finance.yahoo.comCurative Biotechnology, Inc. Names Cary Sucoff to Board of DirectorsMay 12, 2022 | finance.yahoo.comCurative Biotechnology, Inc. Appoints Cary Sucoff to Board of DirectorsMay 4, 2022 | yahoo.comCan You Pay a Mortgage With a Credit Card?May 3, 2022 | finance.yahoo.comCurative Biotechnology Announces Good Laboratory Practice (GLP) Toxicology Studies with Metformin Eye Drop Formulations for Treatment of Macular DegenerationMay 3, 2022 | finance.yahoo.comCurative Biotechnology Announces Toxicology Studies Under Good Laboratory Practices (GLP) for Metformin Eye Drop Formulations for Treatment of Macular DegenerationMarch 21, 2022 | seekingalpha.comCurative signs agreement with NEI to develop age-related eye disease treatmentMarch 21, 2022 | morningstar.comEmily Y. Chew, M.D. of the National Eye Institute Assigned Principal InvestigatorMarch 21, 2022 | finance.yahoo.comCurative Biotechnology Announces Cooperative Research and Development Agreement(CRADA) with the National Eye Institute (NEI) for Clinical Evaluation of its Proprietary Ocular Metformin Formulation in Age-Related Macular DegenerationSee More Headlines Receive CUBT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Curative Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/26/2024Next Earnings (Estimated)5/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Miscellaneous health & allied services, not elsewhere classified Sub-IndustryN/A Current SymbolOTCMKTS:CUBT CUSIPN/A CIK1400271 Webcurativebiotech.com Phone(561) 418-7725Fax866-900-1002EmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares703,260,000Free FloatN/AMarket Cap$19.69 million OptionableNot Optionable Beta-17.73 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesPaul M. MichaelExecutive Chairman & PresidentI. Richard GarrChief Executive Officer & General CounselRon BordensExecutive VP-Technical Operations & ManufacturingBarry A. GinsbergVice Chairman & Chief Strategy OfficerKey CompetitorsPacific Health Care OrganizationOTCMKTS:PFHOBioRestorative TherapiesNASDAQ:BRTXOntrakNASDAQ:OTRKMangoceuticalsNASDAQ:MGRXCryo-Cell InternationalNYSEAMERICAN:CCELView All Competitors CUBT Stock Analysis - Frequently Asked Questions How have CUBT shares performed in 2024? Curative Biotechnology's stock was trading at $0.0213 at the beginning of 2024. Since then, CUBT stock has increased by 31.5% and is now trading at $0.0280. View the best growth stocks for 2024 here. Are investors shorting Curative Biotechnology? Curative Biotechnology saw a increase in short interest in April. As of April 15th, there was short interest totaling 19,400 shares, an increase of 487.9% from the March 31st total of 3,300 shares. Based on an average daily volume of 678,300 shares, the days-to-cover ratio is currently 0.0 days. View Curative Biotechnology's Short Interest. When is Curative Biotechnology's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 6th 2024. View our CUBT earnings forecast. How do I buy shares of Curative Biotechnology? Shares of CUBT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:CUBT) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersFed launches fourth dollar overhaulStansberry ResearchJeff Bezos Just Humiliated Elon MuskInvestorPlaceBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Curative Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
